Chinese Taipei
Hepatitis B
Download HBV dataPrevalence of chronic HBV (HBsAg+)
Children under-5 years
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 0.99 (0.84 - 1.15) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.89 (0.76 - 1.04) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.8 (0.68 - 0.93) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.72 (0.62 - 0.84) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.64 (0.55 - 0.75) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.58 (0.50 - 0.69) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.54 (0.46 - 0.63) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.49 (0.42 - 0.58) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.46 (0.39 - 0.53) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.42 (0.36 - 0.50) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.4 (0.33 - 0.46) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.37 (0.31 - 0.43) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.34 (0.30 - 0.40) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.32 (0.28 - 0.37) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.3 (0.26 - 0.35) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.29 (0.25 - 0.33) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.27 (0.23 - 0.32) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.26 (0.22 - 0.30) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.25 (0.21 - 0.29) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.24 (0.21 - 0.28) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.23 (0.20 - 0.27) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.23 (0.20 - 0.27) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.23 (0.19 - 0.26) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.23 (0.19 - 0.26) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.22 (0.19 - 0.26) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.22 (0.19 - 0.25) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.22 (0.19 - 0.25) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.22 (0.18 - 0.25) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.21 (0.18 - 0.25) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.21 (0.18 - 0.25) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 0.16 (0.18 - 0.13) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 0.16 | 2019 | Survey/reported | Centers for Disease Contro, R.O.C (Taiwan) |
Showing out of
Show more
Number of people living with chronic HBV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 2,182,180 (2,080,480 - 2,281,460) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,177,330 (2,080,540 - 2,269,980) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,173,360 (2,081,930 - 2,262,080) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,171,840 (2,083,320 - 2,263,490) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,174,920 (2,085,720 - 2,267,190) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,182,420 (2,091,090 - 2,284,600) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,182,450 (2,093,650 - 2,276,450) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,170,370 (2,083,980 - 2,262,380) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,155,300 (2,068,360 - 2,242,160) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,144,260 (2,049,610 - 2,234,780) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,143,060 (2,039,350 - 2,239,560) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,140,050 (2,045,460 - 2,230,680) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,127,220 (2,038,020 - 2,216,530) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,113,250 (2,026,480 - 2,203,680) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,104,950 (2,020,740 - 2,201,640) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,107,230 (2,021,920 - 2,213,730) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,105,820 (2,028,040 - 2,196,540) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,092,160 (2,017,420 - 2,179,060) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,076,230 (1,998,440 - 2,163,330) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,066,420 (1,986,800 - 2,158,110) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,069,580 (1,981,410 - 2,165,360) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,068,230 (1,986,680 - 2,157,790) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,051,340 (1,975,720 - 2,135,150) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,030,890 (1,954,320 - 2,112,310) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,015,520 (1,936,110 - 2,095,800) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,012,460 (1,928,250 - 2,099,520) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,964,080 (1,886,240 - 2,045,770) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,917,380 (1,823,720 - 2,009,900) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,919,310 (1,838,940 - 1,998,480) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,925,090 (1,839,460 - 2,006,560) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,855,010 (1,770,560 - 1,933,330) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Number of new cases of HBV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 144 | 2021 | Survey/reported | Centers for Disease Contro, R.O.C (Taiwan) |
HBV-related death rate
National
Download| Value (per 100,000) | Year | Type | Source |
|---|---|---|---|
| 18.31 (16.33 - 20.29) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 18.66 (16.71 - 20.69) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 19.25 (17.28 - 21.32) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 19.57 (17.61 - 21.67) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 20.23 (18.24 - 22.36) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 20.63 (18.56 - 22.74) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 20.8 (18.64 - 22.97) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 19.46 (17.38 - 21.62) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 19.36 (17.17 - 21.65) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 18.56 (16.37 - 20.79) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 18.36 (16.03 - 20.74) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 18.19 (15.97 - 20.52) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 17.06 (14.87 - 19.35) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 18.06 (15.94 - 20.39) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 18.65 (16.37 - 21.03) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 18.89 (16.64 - 21.37) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 18.14 (15.89 - 20.52) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 17.12 (14.91 - 19.58) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15.85 (13.64 - 18.22) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14.69 (12.47 - 16.98) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.99 (11.79 - 16.28) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14.08 (11.90 - 16.44) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.67 (11.48 - 15.97) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.41 (11.26 - 15.69) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.73 (11.55 - 16.05) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 13.55 (11.39 - 15.81) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14.13 (11.86 - 16.52) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 14.62 (11.64 - 17.80) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15.09 (11.44 - 19.45) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15.58 (11.49 - 20.94) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 22 | 2020 | Survey/reported | Ministry of Health and Welfare, Taiwan, ROC |
Showing out of
Show more
HBV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 3,734 (3,330 - 4,139) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,845 (3,443 - 4,263) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,005 (3,596 - 4,436) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,110 (3,697 - 4,550) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,287 (3,866 - 4,740) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,412 (3,970 - 4,865) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,489 (4,025 - 4,958) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,238 (3,785 - 4,708) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,249 (3,768 - 4,751) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,103 (3,619 - 4,597) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,089 (3,571 - 4,620) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,077 (3,581 - 4,600) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,844 (3,351 - 4,360) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,086 (3,607 - 4,615) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,237 (3,719 - 4,778) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,307 (3,795 - 4,872) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4,153 (3,637 - 4,696) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,934 (3,426 - 4,498) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,656 (3,144 - 4,202) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,397 (2,885 - 3,927) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,244 (2,735 - 3,773) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,274 (2,766 - 3,823) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,190 (2,680 - 3,726) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,138 (2,636 - 3,672) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,222 (2,709 - 3,765) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,188 (2,680 - 3,718) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,329 (2,795 - 3,893) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,450 (2,747 - 4,200) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,562 (2,701 - 4,593) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,679 (2,713 - 4,947) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,679 (4,947 - 2,713) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Percent of liver cancer deaths attributable to HBV
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 108 (92 - 125) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 113 (97 - 130) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 117 (100 - 134) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 117 (100 - 133) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 117 (101 - 134) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 114 (98 - 130) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 112 (97 - 128) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 104 (89 - 118) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 115 (99 - 131) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 118 (101 - 135) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 122 (104 - 141) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 121 (103 - 139) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 106 (90 - 122) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 126 (106 - 145) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 130 (110 - 151) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 129 (109 - 150) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 125 (106 - 145) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 113 (96 - 131) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 96 (81 - 112) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 83 (70 - 97) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 73 (62 - 86) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 66 (56 - 78) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 62 (52 - 73) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 60 (50 - 72) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 59 (48 - 71) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 59 (48 - 71) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 60 (49 - 73) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 61 (50 - 75) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 63 (51 - 78) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 64 (51 - 79) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 42 (34 - 51) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
Showing out of
Show more
Coverage of HepB birth dose
Newborns
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 92 | 2020 | Survey/reported | Centers for Disease Contro, R.O.C (Taiwan) |
Coverage of 3-dose hepatitis B vaccine
Infants
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 98 | 2020 | Survey/reported | Centers for Disease Contro, R.O.C (Taiwan) |
Proportion of persons living with HBV diagnosed
Number of persons screened for HBV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 115,000 | 2018 | Survey/reported | Taiwan Health Promotion Administration |
| 146,000 | 2019 | Survey/reported | Taiwan Health Promotion Administration |
| 372,000 | 2020 | Survey/reported | Taiwan Health Promotion Administration |
| 1,234,000 | 2021 | Survey/reported | Taiwan Health Promotion Administration |
Showing out of
Show more
Cumulative number of persons initiating HBV treatment
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 199,000 | 2018 | Survey/reported | Data from Taiwan National Health Insurance Administration |
| 216,000 | 2019 | Survey/reported | Data from Taiwan National Health Insurance Administration |
| 233,000 | 2020 | Survey/reported | Data from Taiwan National Health Insurance Administration |
| 259,000 | 2021 | Survey/reported | Data from Taiwan National Health Insurance Administration |
Showing out of
Show more
Number of persons initiating HBV treatment
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 17,310 | 2018 | Survey/reported | Data from Taiwan National Health Insurance Administration |
| 17,581 | 2019 | Survey/reported | Data from Taiwan National Health Insurance Administration |
| 17,065 | 2020 | Survey/reported | Data from Taiwan National Health Insurance Administration |
| 25,773 | 2021 | Survey/reported | Data from Taiwan National Health Insurance Administration |
Showing out of
Show more
Number of needles/syringes per PWID per year
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 200 | 2020 | Survey/reported | Taiwan Ministry of Health and Welfare |
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes
Year of birth dose introduction
1992
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HBV elimination goal
2025
HCV testing policy
Universal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
Hepatitis C
Download HCV dataPrevalence of chronic HCV (RNA+/cAg)
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 2.01 (1.64 - 2.49) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.01 (1.66 - 2.46) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.02 (1.65 - 2.49) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.04 (1.68 - 2.49) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.07 (1.70 - 2.54) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.19 (1.81 - 2.66) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.43 (2.04 - 2.90) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2.73 (2.32 - 3.20) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.03 (2.59 - 3.52) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.28 (2.81 - 3.77) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.49 (2.98 - 4.01) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.71 (3.18 - 4.25) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.91 (3.37 - 4.49) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.05 (3.50 - 4.68) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.11 (3.55 - 4.77) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.11 (3.56 - 4.75) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.12 (3.57 - 4.76) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.12 (3.58 - 4.76) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.12 (3.57 - 4.74) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.11 (3.56 - 4.74) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 4.07 (3.52 - 4.68) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.97 (3.44 - 4.56) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.85 (3.34 - 4.42) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.73 (3.24 - 4.28) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.63 (3.14 - 4.17) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.55 (3.07 - 4.09) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.47 (2.99 - 4.01) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.39 (2.91 - 3.94) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.32 (2.83 - 3.88) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3.24 (2.73 - 3.84) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1.92 (1.57 - 2.39) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 1 | 2020 | Modelled | CDA Foundation |
Showing out of
Show more
Prevalence of anti-HCV
People who inject drugs (PWID)
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 88.1 | 2021 | Survey/reported | Taiwan National Hepatitis C Program Office |
Number of people living with chronic HCV (RNA+/cAg)
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 624,318 (525,796 - 739,061) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 644,685 (547,484 - 753,956) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 665,884 (571,182 - 773,236) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 687,916 (592,620 - 792,716) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 710,573 (612,511 - 818,731) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 733,666 (632,939 - 846,836) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 760,668 (658,308 - 872,551) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 792,357 (685,161 - 907,758) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 823,856 (711,209 - 946,472) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 849,842 (733,650 - 979,434) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 865,727 (748,949 - 998,530) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 874,211 (756,938 - 1,008,220) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 880,889 (764,299 - 1,017,460) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 885,873 (766,667 - 1,022,520) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 889,999 (770,603 - 1,029,280) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 893,527 (770,488 - 1,037,920) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 885,019 (764,848 - 1,022,770) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 857,599 (740,472 - 983,901) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 817,794 (702,854 - 936,543) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 772,442 (661,493 - 887,824) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 728,394 (624,276 - 839,211) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 676,338 (578,731 - 784,688) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 611,221 (520,004 - 715,701) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 546,073 (458,917 - 649,357) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 493,922 (408,643 - 598,483) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 468,454 (383,893 - 575,863) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 461,864 (381,980 - 565,602) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 458,284 (373,054 - 565,284) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 456,875 (375,940 - 557,908) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 456,135 (372,295 - 566,033) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 453,447 (369,868 - 563,390) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 322,000 | 2016 | Modelled | CDA Foundation |
Showing out of
Show more
Number of new cases of HCV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 561 | 2021 | Survey/reported | Centers for Disease Contro, R.O.C (Taiwan) |
HCV-related death rate
National
Download| Value (Deaths per 100,000) | Year | Type | Source |
|---|---|---|---|
| 6.7 (8.21 - 5.43) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 6.91 (1.09 - 2.03) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.23 (1.10 - 2) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.44 (1.08 - 1.96) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 7.79 (1.08 - 1.94) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.11 (1.09 - 1.95) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.53 (1.09 - 1.94) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.61 (1.10 - 1.98) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.61 (1.09 - 1.98) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.22 (1.09 - 1.98) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.78 (1.07 - 1.99) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.93 (1.06 - 2) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.42 (1.05 - 1.98) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.37 (1.04 - 2.02) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.9 (1.05 - 2.02) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 12.23 (1.03 - 2.02) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.91 (1.04 - 2.03) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 11.41 (1.02 - 2) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.7 (1.02 - 2) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 10.02 (1.02 - 2.01) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.59 (1.02 - 2.04) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.52 (1.03 - 2.06) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.1 (0.98 - 1.96) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.77 (0.94 - 1.89) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.82 (0.89 - 1.84) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 8.69 (0.88 - 1.81) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.07 (0.87 - 1.78) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.32 (0.88 - 1.81) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.57 (0.90 - 1.88) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 9.85 (5.35 - 10.32) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 9.85 (7.23 - 13.23) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 15.1 | 2020 | Survey/reported | Ministry of Health and Welfare, Taiwan, ROC |
Showing out of
Show more
HCV-related deaths
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 1,366 (1,108 - 1,674) | 1990 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,423 (1,161 - 1,749) | 1991 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,503 (1,233 - 1,817) | 1992 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,563 (1,290 - 1,889) | 1993 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,651 (1,368 - 1,996) | 1994 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,734 (1,435 - 2,086) | 1995 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,841 (1,535 - 2,204) | 1996 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 1,875 (1,564 - 2,247) | 1997 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,109 (1,765 - 2,518) | 1998 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,260 (1,904 - 2,687) | 1999 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,401 (2,023 - 2,847) | 2000 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,449 (2,060 - 2,899) | 2001 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,349 (1,980 - 2,787) | 2002 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,573 (2,157 - 3,022) | 2003 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,704 (2,270 - 3,180) | 2004 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,788 (2,339 - 3,286) | 2005 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,725 (2,290 - 3,184) | 2006 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,622 (2,205 - 3,093) | 2007 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,468 (2,071 - 2,918) | 2008 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,318 (1,929 - 2,759) | 2009 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,224 (1,837 - 2,666) | 2010 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,213 (1,816 - 2,645) | 2011 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,123 (1,748 - 2,546) | 2012 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,052 (1,685 - 2,477) | 2013 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,070 (1,694 - 2,503) | 2014 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,043 (1,670 - 2,466) | 2015 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,137 (1,751 - 2,576) | 2016 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,200 (1,755 - 2,726) | 2017 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,261 (1,712 - 2,952) | 2018 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 2,327 (1,708 - 3,124) | 2019 | Modelled | IHME, GBD 2019 (accessed 2022) |
| 3,679 (2,713 - 4,947) | 2019 | Modelled | IHME, GBD 2019 (accessed 2020) |
| 3,560 | 2020 | Survey/reported | Ministry of Health and Welfare, Taiwan, ROC |
Showing out of
Show more
Percent of liver cancer deaths attributable to HCV
National
Download
Showing out of
Show more
Cumulative number of persons treated for HCV
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 9,538 | 2017 | Survey/reported | Taiwan National Hepatitis C Program Office |
| 19,549 | 2018 | Survey/reported | Taiwan National Hepatitis C Program Office |
| 45,806 | 2019 | Survey/reported | Taiwan National Hepatitis C Program Office |
| 36,159 | 2020 | Survey/reported | Taiwan National Hepatitis C Program Office |
| 20,560 | 2021 | Survey/reported | Taiwan National Hepatitis C Program Office |
Showing out of
Show more
Number of needles/syringes per PWID per year
National
Download| Value | Year | Type | Source |
|---|---|---|---|
| 200 | 2020 | Survey/reported | Taiwan Ministry of Health and Welfare |
Proportion of persons living with HCV diagnosed
Proportion of persons living with HCV who have cleared HCV infection
National
Download| Value (%) | Year | Type | Source |
|---|---|---|---|
| 80 | 2020 | Survey/reported | Taiwan National Hepatitis C Program Office |
HBV elimination goal
HBV National Action Plan
HepB birth dose policy
Yes
Year of birth dose introduction
1992
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HBV elimination goal
2025
HCV testing policy
Universal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
No data available
Survey/surveillance
No data available
No data available
Hepatitis related deaths (national)
Modelled
HBV
3,679
2019
(2,713 - 4,947)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
2,327
2019
(1,708 - 3,124)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
HCV
3,560
2020
Ministry of Health and Welfare, Taiwan, ROC
HCV chart
Birth dose vaccination coverage (national)
Survey/surveillance
HBV
92
(%)
2020
Centers for Disease Contro, R.O.C (Taiwan)
No. of syringes/PWID/year
Survey/surveillance
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines